<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00481091</url>
  </required_header>
  <id_info>
    <org_study_id>M06-873</org_study_id>
    <secondary_id>2007-002143-25</secondary_id>
    <nct_id>NCT00481091</nct_id>
  </id_info>
  <brief_title>A Study of ABT-263 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia</brief_title>
  <official_title>A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABT-263 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Phase 1 portion of the study will evaluate the pharmacokinetic profile and safety of&#xD;
      ABT-263 under two different dosing schedules with the objective of defining the dose limiting&#xD;
      toxicity and maximum tolerated dose. The Phase 2a portion of the study will evaluate ABT-263&#xD;
      at the defined recommended Phase 2 dose to obtain additional safety information and a&#xD;
      preliminary assessment of efficacy. The Extension Study portion will allow active subjects to&#xD;
      continue to receive ABT-263 for up to 11 years after the last subject transitions with less&#xD;
      frequent study evaluations.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 25, 2007</start_date>
  <completion_date type="Anticipated">July 8, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 8, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events</measure>
    <time_frame>Up to approximately 13 years</time_frame>
    <description>An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. The investigator assessed the relationship of each event to the use of study drug as either probably related, possibly related, probably not related or not related.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Dose Limiting Toxicity (DLT) in the Dose Escalation Phase (Phase 1)</measure>
    <time_frame>Cycle 1 (Up to 21 days)</time_frame>
    <description>DLTs graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 3.0.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD) in the Dose Escalation Phase (Phase 1)</measure>
    <time_frame>Cycle 1 (Up to 21 days)</time_frame>
    <description>The MTD will be determined by using available clinical data during dose escalation in phase 1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended Phase 2 Dose (RPTD) Determined in the Dose Escalation Phase (Phase 1)</measure>
    <time_frame>Cycle 1 (Up to 21 days)</time_frame>
    <description>The RPTD will be determined based on observed dose-limiting toxicities (DLTs) and/or determination of the maximum tolerated dose (MTD) in phase 1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of Navitoclax (Phase 1)</measure>
    <time_frame>Up to Day 14</time_frame>
    <description>Cmax of navitoclax.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Maximum Observed Plasma Concentration (Tmax) of Navitoclax (Phase 1)</measure>
    <time_frame>Up to Day 14</time_frame>
    <description>Tmax of navitoclax.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal phase elimination rate constant (β) for Navitoclax (Phase 1)</measure>
    <time_frame>Day 1</time_frame>
    <description>Terminal phase elimination rate constant (β) for navitoclax.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal phase elimination half-life (t1/2) of Navitoclax (Phase 1)</measure>
    <time_frame>Day 1</time_frame>
    <description>Terminal phase elimination half-life (t1/2) of navitoclax.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve over time from 0 to 24 hours (AUC0-24) of Navitoclax (Phase 1)</measure>
    <time_frame>Day 1</time_frame>
    <description>AUC0-24 of navitoclax.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve over time from 0 to 8 hours (AUC0-8) of Navitoclax (Phase 1)</measure>
    <time_frame>Day 14</time_frame>
    <description>AUC0-8 of navitoclax.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free Survival (PFS) (Extension Portion)</measure>
    <time_frame>Up to approximately 13 years</time_frame>
    <description>PFS defined as the time from the date the participant started study drug to the date the participant experiences an event of disease progression.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival (OS) (Extension Portion)</measure>
    <time_frame>Up to approximately 13 years</time_frame>
    <description>OS defined as the time from the date the participant started study drug to the date the participant's death.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>Phase 1: Dose Escalation Portion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive escalating doses of ABT-263 to determine the recommended phase 2 dose (RPTD). Eligible participants can continue to receive ABT-263 for 11 years in the extension portion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2a: Dose Expansion Portion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive ABT-263 at the RPTD determined in Phase 1 portion. Eligible participants can continue to receive ABT-263 for 11 years in the extension portion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-263</intervention_name>
    <description>Tablet; Oral</description>
    <arm_group_label>Phase 1: Dose Escalation Portion</arm_group_label>
    <arm_group_label>Phase 2a: Dose Expansion Portion</arm_group_label>
    <other_name>Navitoclax</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Relapsed or refractory Chronic Lymphocytic Leukemia and require treatment in opinion&#xD;
             of investigator.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) &lt;= 1.&#xD;
&#xD;
          -  Adequate bone marrow independent of growth factor support, renal and hepatic function&#xD;
             per defined laboratory criteria.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History or is clinically suspicious for cancer-related Central Nervous System disease.&#xD;
&#xD;
          -  Receipt of allogenic or autologous stem cell transplant.&#xD;
&#xD;
          -  Recent history (within 1 year of first dose) of underlying, predisposing condition of&#xD;
             bleeding or currently exhibits signs of bleeding.&#xD;
&#xD;
          -  Active peptic ulcer disease or other potentially hemorrhagic esophagitis/gastritis.&#xD;
&#xD;
          -  Active immune thrombocytopenic purpura or history of being refractory to platelet&#xD;
             transfusions (within 1 year of first dose).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Moore UC San Diego Cancer Center /ID# 5566</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute /ID# 5547</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ Nebraska Med Ctr /ID# 12261</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore University Hospital /ID# 12267</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center /ID# 5575</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Medical Specialties /ID# 26428</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Ctr /ID# 6583</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital /ID# 5576</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniklinik Koln /ID# 5924</name>
      <address>
        <city>Köln</city>
        <state>Nordrhein-Westfalen</state>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leicester Royal Infirmary /ID# 15081</name>
      <address>
        <city>Leicester</city>
        <state>England</state>
        <zip>LE1 5WW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Germany</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.abbvie.com/our-science/clinical-trials/clinical-trials-data-and-information-sharing/data-and-information-sharing-with-qualified-researchers.html</url>
    <description>Related Info</description>
  </link>
  <reference>
    <citation>Roberts AW, Seymour JF, Brown JR, Wierda WG, Kipps TJ, Khaw SL, Carney DA, He SZ, Huang DC, Xiong H, Cui Y, Busman TA, McKeegan EM, Krivoshik AP, Enschede SH, Humerickhouse R. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol. 2012 Feb 10;30(5):488-96. doi: 10.1200/JCO.2011.34.7898. Epub 2011 Dec 19.</citation>
    <PMID>22184378</PMID>
  </reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 30, 2007</study_first_submitted>
  <study_first_submitted_qc>May 30, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 1, 2007</study_first_posted>
  <last_update_submitted>July 28, 2021</last_update_submitted>
  <last_update_submitted_qc>July 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Lymphocytic Leukemia (CLL)</keyword>
  <keyword>Navitoclax</keyword>
  <keyword>ABT-263</keyword>
  <keyword>Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Navitoclax</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.</ipd_time_frame>
    <ipd_access_criteria>Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.</ipd_access_criteria>
    <ipd_url>https://www.abbvie.com/our-science/clinical-trials/clinical-trials-data-and-information-sharing/data-and-information-sharing-with-qualified-researchers.html</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

